Nyenburgh Investment Partners (NYIP) is founded by Alexander Jordaan, Dave van Mastwijk and Ivar van der Salm. Alexander and Ivar run a family office and together with Nyenburgh Holding B.V., represented by Dave they form a dedicated partnership, Nyenburgh Investment Partners.
With a combined experience of over 50 years in the financial markets, and the expertise of our in-house team of life science analysts, the partnership has an outstanding lever on investing in the comprehensive life sciences sector across Europe.
Alexander started his career at ABN AMRO Bank in The Netherlands, where he joined the asset management division with AUM in excess of EUR 200B. Alexander was part of the equity dealing team, overlooking the execution side of pan-European equity transactions. In 2001 he joined a pan-European hedge fund in London where he was responsible for building equity portfolios focussed on event driven situations as well as deep value strategies. In 2008 he returned to the Netherlands to start his own family office, Omega Capital. At Omega Alexander managed an equity portfolio focussed on 3 specific areas, Biotech, M&A and special situations. In order to optimize the investment opportunities he is one of the three founders of Nyenburgh Investment Partners.
Alexander holds a B.Sc. in Economics and a M.Sc. in Finance.
Dave van Mastwijk
Dave was first employed at MeesPierson Investment Bank, which was then part of ABN AMRO Bank. He was senior advisor to financial institutions worldwide on their equity investments in Europe. Being employed at MeesPierson he felt more compassionate on lifesciences. After MeesPierson he started, joined by a couple of MeesPierson colleagues, at Wedge Asset Management Europe. As he successfully concluded his 5-year mandate he then moved over to Nyenburgh Holding where he was made responsible for the investment portfolio. He now holds this position since 2005, where he has been active in numerous life sciences related capital transactions acting as anchor investor.
Dave holds a B.Sc. in Economics.
Ivar van der Salm
Ivar started his career at Fortis investments in Amsterdam, servicing private client portfolios in bonds and equities. He then switched to Delta Lloyd Bank, to oversee the sales trading business in European equities serving Tier-1 clients from London, New York and Frankfurt. In 1999 he joined Eureffect to become partner and overlooking the professional clients business, with a focus on Tech, Media and Telco. After running this business for 5 years he was made co-responsible for the highly successful hedge fund business within the company. Overlooking up to a 100 mln in assets and growing, he decided to start his own business and founded Tay Capital. The company is running a portfolio in equities and focuses on life science, M&A and deep value investment strategies.
Ivar holds a B.Sc. in Economics and obtained a RBA Title on the Amsterdam University, a post graduate education equivalent to the the American CFA title.
Gert-Daniël van der Schors
Gert joined Nyenburgh Investment Partners in April 2015 as a Life Science Analyst. Trained as health and life scientist, he acquired substantial knowledge in the areas of health care, health economics, clinical trials, infectious diseases, neuroscience and genetics. At Nyenburgh Investment Partners, Gert analyzes the scientific background of investment cases, to address some of the risk inherently associated with life science companies.
Gert holds a MSc in Biomedical Sciences from Vrije Universiteit in Amsterdam.
Sjoerd van Rijn
As the latest addition to the team, Sjoerd was appointed as Life Science analyst to strengthen the scientific and technical background of NYIP. Sjoerd is originally trained as a biomedical scientist with a focus in oncology research and acquired extensive experience as an academic researcher in various internationally recognized research institutes. He now utilizes his experience at NYIP for risk assessment of biotech investments. Sjoerd obtained a PhD. from the VU University in Amsterdam.